Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Blood (2024) 144 (Supplement 1): 318.

https://doi.org/10.1182/blood-2024-199017

Published: 2024

Journal Articles

Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)

Julia Costea, Kerstin K. Rauwolf, Pietro Zafferani, Tobias Rausch, Anna Mathioudaki, Judith Zaugg, Martin Schrappe, Cornelia Eckert, Gabriele Escherich, Jean-Pierre Bourquin, Beat Bornhauser, Andreas E. Kulozik, Jan O. Korbel

Blood (2024) 144 (Supplement 1): 314.

https://doi.org/10.1182/blood-2024-199619

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Blood (2024) 144 (Supplement 1): 968.

https://doi.org/10.1182/blood-2024-198419

Published: 2024

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Fabio D. Steffen, Iria Anne Jimenez, Yun Huang, Kerstin K. Rauwolf, Arijit Chakraborty, Shekhar Krishnan, Vaskar Saha, Beat Bornhauser, Jean-Pierre Bourquin

Blood (2023) 142 (Supplement 1): 417.

https://doi.org/10.1182/blood-2023-172885

Published: 2023

Journal Articles

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Arijit Chakraborty, Parag Das, Manash Pratim Gogoi, Tanima Dey, Fabio D. Steffen, Sangramjit Basu, Debdutta Ganguli, Debjani Ghosh, Niharendu Ghara, Subhajit Kundu, Abhirupa Kar, Beat Bornhauser, Jean-Pierre Bourquin, Vaskar Saha, Shekhar Krishnan

Blood (2023) 142 (Supplement 1): 4244.

https://doi.org/10.1182/blood-2023-185989

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Blood (2023) 142 (Supplement 1): 730.

https://doi.org/10.1182/blood-2023-181593

Published: 2023

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Lennart Lenk, Irène Baccelli, Dorothee Winterberg, Anna Dietterle, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Anna Laqua, Beat Bornhauser, Jean-Pierre Bourquin, Fotini Vogiatzi, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe

Blood (2022) 140 (Supplement 1): 1045–1047.

https://doi.org/10.1182/blood-2022-162261

Published: 2022

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Britt M T Vervoort, Miriam Butler, Dorette van Ingen Schenau, Vincent H.J. van der Velden, Beat Bornhauser, Jean-Pierre Bourquin, Laurens T van der Meer, Frank N van Leeuwen

Blood (2022) 140 (Supplement 1): 3465–3466.

https://doi.org/10.1182/blood-2022-162246

Published: 2022

Journal Articles

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Blood (2022) 140 (1): 45–57.

https://doi.org/10.1182/blood.2021014485

Published: 2022

Includes: Supplemental data

Journal Articles

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

Miriam Butler, Dorette S. van Ingen Schenau, Jiangyan Yu, Silvia Jenni, Maria P. Dobay, Rico Hagelaar, Britt M. T. Vervoort, Trisha M. Tee, Fieke W. Hoff, Jules P. Meijerink, Steven M. Kornblau, Beat Bornhauser, Jean-Pierre Bourquin, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen

Blood (2021) 138 (23): 2383–2395.

https://doi.org/10.1182/blood.2021011787

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Blood (2021) 138 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2021-145709

Published: 2021

Journal Articles

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Blood (2021) 138 (9): 773–784.

https://doi.org/10.1182/blood.2020010510

Published: 2021

Includes: Supplemental data

NARROW

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only